Big Call Scan: Sanofi, Vinci Constructions, SAP, RTX
Reading Time: 2 minutes
Values in defensive sectors are coming into focus as the trade dispute between the USA and China continues to escalate. Among these, the French pharmaceutical company Sanofi remains a favorite, especially due to its two blockbuster drugs, Dupixient and Beyfortus, as well as its promising pipeline which offers excellent prospects. Furthermore, fundamentally, Sanofi impresses with its attractive valuation, making it a favorite in the pharmaceutical sector on the selection list of "The Big Call". The price action at Vinci currently looks very bullish....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
